STOCK TITAN
  1. Home
  2. Financials
  3. RNAZ
  4. EPS (Diluted)

TransCode Therapeutics, Inc. (RNAZ) EPS by Year

RNAZ

TransCode Therapeutics, Inc. lost $52.59 per diluted share in fiscal year 2025. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters TransCode Therapeutics, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$52.59
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RNAZ EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
EPS (Diluted)-$52.59-$1336.63-$3419.01-$1082.79-$0.81-$0.51

RNAZ EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)-$7.17-$21.28-$18.10-$5.82-$5.13-$70.16-$45.93-$146.06-$680.23-$21.35-$95.15-$48.44

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More TransCode Therapeutics, Inc. financials

Frequently Asked Questions

What was TransCode Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?

TransCode Therapeutics, Inc. lost $52.59 per diluted share in fiscal year 2025.

How has TransCode Therapeutics, Inc.'s diluted earnings per share changed over the years?

Across the 6 fiscal years this page covers, TransCode Therapeutics, Inc. (RNAZ) diluted earnings per share went from -$0.51 in fiscal year 2020 to -$52.59 in fiscal year 2025.

What was TransCode Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?

TransCode Therapeutics, Inc. (RNAZ) reported -$7.17 in diluted earnings per share in Q2 2026.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what TransCode Therapeutics, Inc. (RNAZ) reported on that line in every period on record.